Insmed, Inc. (INSM) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts remain broadly bullish: Insmed has a “Moderate Buy” consensus from 25 analysts, with 22 buy ratings and an average 12-month price target of $200.30.
• Quarterly results exceeded expectations: Insmed reported adjusted earnings of $(0.06) per share versus the $(0.67) consensus estimate, while revenue rose 296.1% year over year to $425.49 million.
• Shares have declined and insiders sold stock: The stock opened at $95.29, near its 12-month low of $90.39 and well below its $212.75 high. The COO and a director sold shares, reducing their holdings by about 70.8% and 38.9%, respectively.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-five analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $200.30.

A number of equities research analysts have recently issued reports on INSM shares. Guggenheim reduced their price target on shares of Insmed from $207.00 to $205.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. UBS Group reaffirmed a "buy" rating on shares of Insmed in a research report on Thursday, October 8th. Truist Financial reaffirmed a "buy" rating and set a $195.00 price objective (up from $185.00) on shares of Insmed in a research report on Monday, August 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Insmed in a report on Thursday. Finally, Bank of America reiterated a "buy" rating and issued a $207.00 target price on shares of Insmed in a report on Monday, October 12th.

Insmed Stock Down 1.0%

Shares of INSM opened at $95.29 on Tuesday. The firm has a market cap of $20.81 billion, a P/E ratio of -23.18 and a beta of 0.83. Insmed has a 12-month low of $90.39 and a 12-month high of $212.75. The company's 50-day moving average price is $117.99 and its 200 day moving average price is $117.54. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. Insmed's revenue was up 296.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.70) earnings per share. On average, sell-side analysts forecast that Insmed will post -1.72 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares of the company's stock, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David R. Brennan sold 25,000 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently bought and sold shares of the company. Sei Investments Co. raised its stake in Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock worth $228,239,000 after acquiring an additional 505,624 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in Insmed by 14.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company's stock valued at $178,659,000 after acquiring an additional 143,285 shares during the last quarter. NWI Management LP boosted its stake in Insmed by 2.6% in the first quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company's stock valued at $165,809,000 after acquiring an additional 25,540 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Insmed by 18.8% in the first quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company's stock valued at $149,860,000 after acquiring an additional 145,106 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Insmed by 480.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company's stock valued at $144,591,000 after acquiring an additional 1,048,518 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed's lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.